Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms

Autor(es):Mostrar menos -

Schmitt, Andrea ; Martins-de-Souza, Daniel ; Akbarian, Schahram ; Cassoli, Juliana S. ; Ehrenreich, Hannelore ; Fischer, Andre ; Fonteh, Alfred ; Gattaz, Wagner F. ; Gawlik, Michael ; Gerlach, Manfred ; Grunblatt, Edna ; Halene, Tobias ; Hasan, Alkomiet ; Hashimoto, Kenij ; Kim, Yong-Ku ; Kirchner, Sophie-Kathrin ; Kornhuber, Johannes ; Kraus, Theo F. J. ; Malchow, Berend ; Nascimento, Juliana M. ; Rossner, Moritz ; Schwarz, Markus ; Steiner, Johann ; Talib, Leda ; Thibaut, Florence ; Riederer, Peter ; Falkai, Peter ; Force, Members WFSBP Task

• Tipo de documento: Artigo Científico
• Fonte: WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY; v. 18, n. 5, p. 330-356, 2017.
• Citações Web of Science: 7

Resumo

Objectives: Despite progress in identifying molecular pathophysiological processes in schizophrenia, valid biomarkers are lacking for both the disease and treatment response. Methods: This comprehensive review summarises recent efforts to identify molecular mechanisms on the level of protein and gene expression and epigenetics, including DNA methylation, histone modifications and micro RNA expression. Furthermore, it summarises recent findings of alterations in lipid mediators and highlights inflammatory processes. The potential that this research will identify biomarkers of schizophrenia is discussed. Results: Recent studies have not identified clear biomarkers for schizophrenia. Although several molecular pathways have emerged as potential candidates for future research, a complete understanding of these metabolic pathways is required to reveal better treatment modalities for this disabling condition. Conclusions: Large longitudinal cohort studies are essential that pair a thorough phenotypic and clinical evaluation for example with gene expression and proteome analysis in blood at multiple time points. This approach might identify biomarkers that allow patients to be stratified according to treatment response and ideally also allow treatment response to be predicted. Improved knowledge of molecular pathways and epigenetic mechanisms, including their potential association with environmental influences, will facilitate the discovery of biomarkers that could ultimately be effective tools in clinical practice. (AU)

• Processo FAPESP: 13/08711-3 - Desenvolvimento de um teste preditivo para medicação bem sucedida e compreensão das bases moleculares da esquizofrenia através da proteômica
• Beneficiário: Daniel Martins-de-Souza
• Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores
• Processo FAPESP: 14/10068-4 - EMU concedido no processo 13/08711-3: espectrômetro de massas Waters SYNAPT G2-Si HDMs + nanoACQUITY UPLC
• Beneficiário: Daniel Martins-de-Souza
• Linha de fomento: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 14/14881-1 - Compreensão da influência de componentes da via glicolítica na função dos oligodendrócitos: uma relação com os achados em esquizofrenia
• Beneficiário: Juliana Silva Cassoli
• Linha de fomento: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 14/21035-0 - Proteômica quantitativa de linhagens neurais e organóides cerebrais derivados de células tronco de pluripotência induzida de pacientes com esquizofrenia
• Beneficiário: Juliana Minardi Nascimento
• Linha de fomento: Bolsas no Brasil - Pós-Doutorado